Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis.
OBJECTIVE
To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP).


METHODS
Open, randomized, controlled study.


METHODS
Phototherapy unit in a dermatology hospital.


METHODS
Fifty-four patients with CCP.


METHODS
Patients received whole-body threshold erythemogenic dose of either 3-times weekly TL-01 or twice-weekly oral 8-MOP PUVA, based on minimal erythema or phototoxic doses. Patients were treated until completely clear.


METHODS
Number of treatments to clear, number of days in treatment, number of days in remission, and adverse effects of both therapies were assessed.


RESULTS
Forty-five patients completed the study. Those in the PUVA group required significantly fewer treatments to clear (P =.03). There was no significant difference in the number of days to clear or number of days in remission. A similar percentage of patients in the TL-01 and PUVA groups developed minimal perceptible erythema, showing that the regimens were equally erythemogenic. Asymptomatic, well-defined erythema occurred only in the PUVA group. Pruritus and polymorphic light eruption occurred equally in both groups, but only patients in the PUVA group developed nausea.


CONCLUSIONS
Narrowband UV-B phototherapy, used 3 times weekly, is as effective for the treatment of CPP as oral 8-MOP PUVA used twice weekly.
Markham
T
T
City of Dublin Skin and Cancer Hospital, Hume St, Dublin 2, Ireland. trevormarkham@hotmail.com
Rogers
S
S
Collins
P
P
D000284:Administration, Oral; D000328:Adult; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008730:Methoxsalen / Q000008:administration & dosage; D008875:Middle Aged; D017319:Photosensitizing Agents / Q000008:administration & dosage; D011565:Psoriasis / Q000473:pathology / Q000532:radiotherapy*; D011874:Radiometry; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014466:Ultraviolet Rays; D014467:Ultraviolet Therapy; D014916:Whole-Body Irradiation
D017319:Photosensitizing Agents; D008730:Methoxsalen